A phase II trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303)

BACKGROUND: Bortezomib, an inhibitor of the 26S proteasome and NF-κB, may have antitumor activity in adenoid cystic carcinoma (ACC). Preclinical studies have shown synergy between bortezomib and doxorubicin. METHODS: Eligibility criteria included incurable ACC, any number of prior therapies but with...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Argiris, Athanassios, Ghebremichael, Musie, Burtness, Barbara, Axelrod, Rita S., Deconti, Ronald C., Forastiere, Arlene A.
Формат: Artigo
Язык:Inglês
Опубликовано: 2011
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3135694/
https://ncbi.nlm.nih.gov/pubmed/21246525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25852
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы